Alterity Therapeutics Limited

NasdaqCM ATHE

Alterity Therapeutics Limited Shares (Diluted, Weighted) for the year ending June 30, 2024: 3,648,875,564

Alterity Therapeutics Limited Shares (Diluted, Weighted) is 3,648,875,564 for the year ending June 30, 2024, a 50.29% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.
  • Alterity Therapeutics Limited Shares (Diluted, Weighted) for the year ending June 30, 2023 was 2,427,841,917, a 0.91% change year over year.
  • Alterity Therapeutics Limited Shares (Diluted, Weighted) for the year ending June 30, 2022 was 2,405,990,036, a 41.79% change year over year.
  • Alterity Therapeutics Limited Shares (Diluted, Weighted) for the year ending June 30, 2021 was 1,696,876,324, a 89.62% change year over year.
  • Alterity Therapeutics Limited Shares (Diluted, Weighted) for the year ending June 30, 2020 was 894,872,224, a 45.33% change year over year.
Key data
Date Shares (Diluted, Weighted) Revenue Cost of Revenue Gross Profit
Market news
Loading...
NasdaqCM: ATHE

Alterity Therapeutics Limited

CEO Dr. David A. Stamler M.D.
IPO Date Sept. 29, 2003
Location Australia
Headquarters 460 Bourke Street
Employees 10
Sector Health Care
Industries
Description

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Similar companies

RVPH

Reviva Pharmaceuticals Holdings, Inc.

USD 1.58

-17.28%

RNAZ

TransCode Therapeutics, Inc.

USD 3.36

5.66%

SRZN

Surrozen, Inc.

USD 11.19

-1.15%

MNPR

Monopar Therapeutics Inc.

USD 24.98

-2.76%

ANTX

AN2 Therapeutics, Inc.

USD 1.22

-3.17%

TARA

Protara Therapeutics, Inc.

USD 5.03

-5.27%

VCNX

Vaccinex, Inc.

USD 1.05

0.00%

ADIL

Adial Pharmaceuticals, Inc.

USD 1.02

0.99%

ANEB

Anebulo Pharmaceuticals, Inc.

USD 1.60

5.96%

PMVP

PMV Pharmaceuticals, Inc.

USD 1.35

-2.88%

ATXI

Avenue Therapeutics, Inc.

USD 1.88

-1.05%

StockViz Staff

January 15, 2025

Any question? Send us an email